ANNEXON INC (ANNX)
Health Care · Neuroinflammation and complement-targeted biopharmaceuticals · NASDAQ
A clinical-stage biotech company developing complement pathway-targeted therapies for severe neurological and autoimmune disorders.
What ANNEXON INC does
Annexon is a clinical-stage biopharmaceutical company developing product candidates for use in treating severe acute neurological and autoimmune disorders. The company's pipeline is focused on complement pathway modulation, a key mechanism underlying inflammation in neurological conditions. Annexon is advancing multiple candidates through clinical development with the goal of addressing patient populations with limited therapeutic options.
Themes: ["Neuroinflammation","Complement pathway inhibition","Autoimmune disorders","Clinical-stage biotech"]
Fundamentals
- Price$5.94 as of 2026-07-09 close
- Market cap$967M as of 2026-07-10
- 1-year return+119.9% as of 2026-07-09 close
- ROE-101.2% as of 2026-07-10
- Debt / equity0.00 as of 2026-07-10
- Beta1.17 as of 2026-07-10
Key risks (from latest filing)
["Clinical development and regulatory approval risk; the company is primarily focused on clinical-stage candidates with uncertain outcomes and timelines for regulatory approval","Limited operating history and substantial accumulated deficit; the company has generated net losses every period and has accumulated deficit of approximately $961.5 million as of Q1 2026","Dependency on continued financing; the company has limited cash runway and will require additional capital raises to fund ongoing clinical development and operations"]
Competitors & peers
- Complement Therapeutics
- Apellis Pharmaceuticals (APLS)
- Achillion Pharmaceuticals
- Ra Pharmaceuticals
- Iteration Therapeutics
Fundamentals: Finnhub, as of 2026-07-10. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-09.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & Finnhub, shown with their as-of date.